At the KAHN CENTER, we have recommended PROLON, the 5 Day Fasting Mimicking Diet (FMD) since early 2017. Dr. Kahn has completed 30 rounds of PROLON over those years, about 4 times a year. He has lead online group support sessions for the FMD community. It is without a doubt the safest and most supported "longevity" activity you can add on. Dr. Kahn offers PROLON at www.prolonlife.com/drkahn and suggests the NEXT GEN version. The parent company, L-Nutra, is celebrating the 10th anniversary of the release of PROLON.
L-Nutra Inc., a leading pioneer in longevity nutrition and nutrition as medicine, today marked the tenth anniversary of Prolon®, its clinically studied Fasting Mimicking Diet (FMD). The company's mission has been the same since day one: give people the chance to live 100 healthy years. A decade of scientific firsts and global growth has made L-Nutra's body of longevity research unmatched in the category.
In two recent human trials, Prolon® became the first nutrition program shown to induce autophagy - the cellular renewal process whose discovery earned the 2016 Nobel Prize in Physiology or Medicine - and to reverse biological age by an average of 2.5 years after three consecutive cycles, a critical milestone in extending healthspan.
No other company matches L-Nutra and Prolon®'s longevity science. The company holds:
"Our longevity scientists, alongside researchers at 18 top global medical centers, have been conducting groundbreaking nutri-tech R&D for more than two decades under the leadership of Professor Valter Longo - one of TIME's 100 Most Influential People in Health and Director of the Longevity Institute at University of Southern California," said Dr. Joseph Antoun, CEO of L-Nutra. "We pioneered the longevity category before it became mainstream, and we're committed to turning food into a true asset for longevity and medicine - becoming the first nutrition company people turn to every day, whether they're healthy or managing an illness."
L-Nutra's science extends beyond the 5-Day FMD that built Prolon®'s reputation. The company's nutri-technology platform now spans every day nutrition including: longevity foods, medical nutrition therapy, and precision nutrition for every life stage, all aimed at the same goal: giving people the chance to live longer in good health, not just longer.
Since Prolon®'s introduction in 2016, the same year autophagy's mechanisms won the Nobel Prize in Physiology or Medicine, its 5-Day Fasting Mimicking Diet has been used by more than one million people to trigger autophagy, the cell's natural recycling and renewal process, and reverse biological age by an average of 2.5 years after three consecutive cycles. As L-Nutra looks to the next decade, the goal is to extend that impact to 100 million people.
L-Nutra is a leader in longevity and nutrition science, pioneering innovations that unlock the power of nutrition to support healthy aging, combat age-related conditions, and transform lives. Founded in 2009 by Professor Valter Longo, L-Nutra's research has given rise to groundbreaking fasting nutrition programs and clinically validated solutions that are reshaping the future of healthcare, employee wellness, and disease prevention. Under the leadership of Dr. Joseph Antoun, who launched the first longevity-focused investment fund in 2011 and has since helped raise more than $150 million for longevity-focused companies, L-Nutra has generated over a quarter billion dollars in sales and helped establish food as medicine as a clinically validated, commercial category. The company holds 136 patents in longevity and disease remission and has conducted 40+ clinical trials in partnership with leading research institutions including Stanford, USC, Mayo Clinic, and Harvard. Through Prolon®, the first commercially available Fasting Mimicking Diet program, and L-Nutra Health, its healthcare division delivering 360-degree, physician-guided programs to reverse age-related disease, the company is bringing the science of longevity to the world, one cell, one person, and one organization at a time
L-Nutra's footprint now extends well beyond the United States, with a growing presence across Europe, Canada, and Australia, alongside its expanding work in the Middle East. Earlier this year, L-Nutra closed a Series D raise totaling $83.5 million, led by Mubadala Investment Company, one of the world's most prominent sovereign investors, fueling continued investment in research and global expansion.
At the KAHN CENTER, we will continue to recommend PROLON as part of a longevity program. This program is a shining example of Food as Medicine.
